Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer

Anti-Cancer Drugs

Volumn 13, Issue 9, 2002, Pages 931-938

  Sugiyama, Yasuyuki ^a,b   Kato, Tomoyuki ^a   Nakazato, Hiroaki ^a   Ito, Katsuki ^a   Mizuno, Isamu ^a   Kanemitsu, Taiseki ^a   Matsumoto, Kouichi ^a   Yamaguchi, Akihiro ^a   Nakai, Katsuhiko ^a   Inada, Ken Ichi ^a   Tatematsu, Masae ^a  

^a Stud Grp TAC Col Can (TAC CR)   (Japan)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant chemotherapy and UFT; Colorectal cancer; Retrospective study; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; TEGAFUR; THYMIDYLATE SYNTHASE; UFT; URACIL; TUMOR MARKER;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COLON RESECTION; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; ENZYMOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TEGAFUR; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL; URACIL;

EID: 0036812810     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200210000-00005     Document Type: Article

References (21)

1. Danenberg PV. Thymidylate synthase: A target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977; 473: 73-92.
2. Santi DV, McHenry CS, Sommer H. Mechanisms of interaction on thymidylate synthase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13: 471-80.
3. Danenberg PV, Langenbach RJ, Heidelberger C. Structure of reversible and irreversible complexes of thymidylate synthase and fluoropyrimidine nucleotides. Biochemistry 1974; 13: 926-33.
4. Washtein WL. Increased levels of thymidylate synthase in cells exposed to 5-fluorouracil. Mol Pharmacol 1984; 25: 171-7.
5. Clark JL, Berger SL, Mittelman A, Berger FG. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 1987; 71: 261-5.
6. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell line. Cancer Res 1992; 52: 4306-12.
7. Cascinu S, Aschele C, Barni S, et al. Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999; 5: 1996-9.
8. Pestalozzi BC, Peterson HF, Gelber RD, et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997; 15: 1923-31.
9. Suda Y, Kuwashima Y, Tanaka Y, et al. Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: A prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines. Anticancer Res 1999; 9: 805-10.
10. Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-7.
11. Findlay MP, Cunningham D, Morgan G, et al. Lack of correlation between thymidylate synthase levels in primary colorectal tumors and subsequent response to chemotherapy. Br J Cancer 1997; 75: 903-9.
12. Kato T, Ohashi Y, Nakazato H, et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: Multicenter prospective randomized trial. Langenbeck's Arch Surg 2002; 386: 575-81.
13. Johnston PG, Mick R, Recant W, et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997; 89: 308-13.
14. Yeh KH, Shun CT, Chen CL, et al. High expression of thymidylate synthase is associated the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998; 82: 1626-31.
15. Yamachika T, Nakanishi H, Inada K, et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998; 82: 70-7.
16. Okabe H, Tsujimoto H, Fukushima M. Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity-study of 5-fluorouracil. Oncol Rep 1997; 4: 685-90.
17. Okabe H, Tsujimoto H, Fukushima M. The correlation between thymidylate synthase expression and cytotoxicity of 5-fluorouracil in human cancer cell line: Study using polyclonal antibody against recombinant human thymidylate synthase. Jpn J Cancer Chemother 1997; 24: 705-12.
18. Kuniyasu T, Nakamura T, Tabuchi Y, et al. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: The clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 1998; 83: 1300-6.
19. Suzuki M, Tsukagoshi S, Saga Y, et al. Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology 1999; 57: 50-4.
20. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology 1999; 13(suppl 3): 17-21.
21. Hoff PM, Pazdur R. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: A novel class of oral antineoplastic agents. Semin Oncol 1999; 26(suppl 18): 52-6.